Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

Open access
Corgnac, Stéphanie, Malenica, Ines, Mezquita, Laura, Auclin, Edouard, Voilin, Elodie, Kacher, Jamila, Halse, Heloise, Grynszpan, Laetitia, Signolle, Nicolas, Dayris, Thibault, Leclerc, Marine, Droin, Nathalie, de Montpréville, Vincent, Mercier, Olaf, Validire, Pierre, Scoazec, Jean-Yves, Massard, Christophe, Chouaib, Salem, Planchard, David, Adam, Julien, Besse, Benjamin, Mami-Chouaib, Fathia · 2020 · Cell Reports Medicine

Abstract

Accumulation of CD103 + CD8 + resident memory T (T RM ) cells in human lung tumors has been associated with a favorable prognosis. However, the contribution of T RM to anti-tumor immunity and to the response to immune checkpoint blockade has not been clearly established. Using quantitative multiplex immunofluorescence on cohorts of non-small cell lung cancer patients treated with anti-PD-(L)1, we show that an increased density of CD103 + CD8 + lymphocytes in immunotherapy-naive tumors is associated with greatly improved outcomes. The density of CD103 + CD8 + cells increases during immunotherapy in most responder, but not in non-responder, patients. CD103 + CD8 + cells co-express CD49a and CD69 and display a molecular profile characterized by the expression of PD-1 and CD39. CD103 + CD8 + tumor T RM , but not CD103 − CD8 + tumor-infiltrating counterparts, express Aiolos, phosphorylated STAT-3, and IL-17; demonstrate enhanced proliferation and cytotoxicity toward autologous cancer cells; and frequently display oligoclonal expansion of TCR-β clonotypes. These results explain why CD103 + CD8 + T RM are associated with better outcomes in anti-PD-(L)1-treated patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2020.100127

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 182

Metadata

Authors
Corgnac, S., Malenica, I., Mezquita, L., Auclin, E., Voilin, E., Kacher, J., Halse, H., Grynszpan, L., Signolle, N., Dayris, T., Leclerc, M., Droin, N., de Montpréville, V., Mercier, O., Validire, P., Scoazec, J.-Y., Massard, C., Chouaib, S., Planchard, D., Adam, J., Besse, B., & Mami-Chouaib, F.
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2020-10
Volume
1
Issue
7
Pages
100127
ISSN
2666-3791 (ISSN-L)
OpenAlex
W3094376062
Cited by
182
References
25
FWCI
5.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. https://app.cochat.ai/papers/10.1016/j.xcrm.2020.100127
The paper
Corgnac, S., Malenica, I., Mezquita, L., Auclin, E., Voilin, E., Kacher, J., Halse, H., Grynszpan, L., Signolle, N., Dayris, T., Leclerc, M., Droin, N., de Montpréville, V., Mercier, O., Validire, P., Scoazec, J.-Y., Massard, C., Chouaib, S., Planchard, D., . . . Mami-Chouaib, F. (2020). CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2020.100127

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.